The Southwest Oncology Group Cancer Research Program will be carried out in cooperation with other member institutions as well as CCOP and CGOP participants of the Southwest Oncology Group. It involves the combined modality approach to the management of adult patients with malignant disease. The Principal Investigator and other participants in this effort have a broad experience in cooperative therapeutic research. The commitment is to accrual of patients to combined modality research protocols with participants from Medical Oncology, Hematology, Surgical Oncology, Pathology, and Radiation Oncology being involved. The estimated accrual will be in excess of 185 new patients to Southwest Oncology Groups studies within the first year. In addition to cancer therapeutic research, the University of Texas Health Science Center at San Antonio will accrue an estimated 932 patients or clients (583.85 credits) to cancer control research concepts. The investigators listed above have made major contributions in science and the administration of the Southwest Oncology Group: Chair of the Southwest Oncology Group (Charles A. Coltman, Jr., M.D.); Principal Investigator of the Southwest Oncology Group institutional grant (Charles A. Coltman, Jr., M.D.); Executive Office, Southwest Oncology Group (Geoffrey R. Weiss, M.D.); Associate Executive Officer, Southwest Oncology Group (Johnny B. Craig, M.D.); Chair, Quality Assurance Committee (Geoffrey R. Weiss, M.D.); Chair, Breast Cancer Committee (C. Kent Osborne, M.D.); Associate Chair, Breast Cancer Committee (William L. McGuire, M.D.); Chair, Surgical Quality Control Committee (Anatolio B. Cruz, Jr., M.D.). This provides clear evidence of major scientific and administrative leadership in the Southwest Onocology Group in addition to the registration of patients on combined modality studies at this institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA022433-13
Application #
3556654
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1978-01-01
Project End
1992-12-31
Budget Start
1990-01-01
Budget End
1990-12-31
Support Year
13
Fiscal Year
1990
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Messing, Edward M; Tangen, Catherine M; Lerner, Seth P et al. (2018) Effect of Intravesical Instillation of Gemcitabine vs Saline Immediately Following Resection of Suspected Low-Grade Non-Muscle-Invasive Bladder Cancer on Tumor Recurrence: SWOG S0337 Randomized Clinical Trial. JAMA 319:1880-1888
Samlowski, Wolfram E; Moon, James; Witter, Merle et al. (2017) High frequency of brain metastases after adjuvant therapy for high-risk melanoma. Cancer Med 6:2576-2585
Sonpavde, Guru; Pond, Gregory R; Plets, Melissa et al. (2017) Validation of the Association of RECIST Changes With Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated on SWOG Study S0421. Clin Genitourin Cancer 15:635-641
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952
Durie, Brian G M; Hoering, Antje; Abidi, Muneer H et al. (2017) Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet 389:519-527
Lee, Sylvia M; Moon, James; Redman, Bruce G et al. (2015) Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933. Cancer 121:432-440
Goldkorn, Amir; Ely, Benjamin; Tangen, Catherine M et al. (2015) Circulating tumor cell telomerase activity as a prognostic marker for overall survival in SWOG 0421: a phase III metastatic castration resistant prostate cancer trial. Int J Cancer 136:1856-62
Barr, Paul M; Li, Hongli; Spier, Catherine et al. (2015) Phase II Intergroup Trial of Alisertib in Relapsed and Refractory Peripheral T-Cell Lymphoma and Transformed Mycosis Fungoides: SWOG 1108. J Clin Oncol 33:2399-404
Blumenthal, Deborah T; Rankin, Cathryn; Stelzer, Keith J et al. (2015) A Phase III study of radiation therapy (RT) and O?-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. Int J Clin Oncol 20:650-8

Showing the most recent 10 out of 257 publications